The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe